- Details
- Evan Yu joins Zachary Klaassen to discuss the results of the ARROW trial. The study evaluates Iodine-131-LNTH-1095, a novel PSMA radioligand therapy, in combination with enzalutamide versus enzalutamide alone for metastatic castration-resistant prostate cancer patients who previously received abiraterone. While the trial meets its primary endpoint with significantly higher PSA decline rates in the...
|
- Details
- Oliver Sartor hosts Jake Berchuck to discuss a novel epigenomic liquid biopsy platform for determining PSMA expression in prostate cancer. Dr. Berchuck explains how the assay analyzes cell-free DNA to infer tumor PSMA expression, showing strong correlation with PSMA PET scan results. They explore the potential of this technology to provide real-time, non-invasive monitoring of tumor drug target ex...
|
- Details
- Oliver Sartor and Ken Herrmann discuss the current state and future directions of PSMA ligand therapy in prostate cancer treatment. Dr. Herrmann presents recent findings from various clinical trials, including PSMAfore and ENZA-p, which explore the use of lutetium-PSMA therapy in different stages of prostate cancer. They examine the potential of combining lutetium-PSMA with other treatments like e...
|
- Details
- Oliver Sartor interviews John Valliant about the potential of radiopharmaceuticals in cancer treatment. Dr. Valliant discusses the advantages of targeted radiation therapy, particularly using Actinium-225, highlighting its efficacy and potential for combination therapies. He emphasizes the unique ability of radiopharmaceuticals to combine imaging and treatment, allowing for better patient selectio...
|
- Details
- Scott Tagawa discusses the final results of a phase I/II trial exploring dose-escalation of lutetium PSMA for advanced prostate cancer. Launched in 2017, this trial aimed to determine the safety and efficacy of increasing radioactive doses in a fractionated, dose-dense regimen to maintain constant tumor exposure. The study escalated doses from 7.4 to 22.2 gigabecquerels without reaching a dose-lim...
|
- Details
- Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice. He notes that while ligands like Gallium PSMA-11 and DCFPyL are similar and FDA-approved, others like PSMA-1007, although widely used...
|
- Details
- Alicia Morgans speaks with Louise Emmett about the use of radiopharmaceuticals in prostate cancer, particularly for frail patients. Professor Emmett focuses on dosing radioligand therapy in special situations and managing toxicity, particularly marrow and kidney toxicity. She highlights the need for individualized dosing strategies, noting that current protocols might not adequately treat high-vol...
|
- Details
- Phillip Koo hosts a discussion on patient selection for radioligand therapy (RLT) in prostate cancer, featuring Amir Iravani and Evan Yu. The conversation delves into complex clinical decisions involving advanced prostate cancer management. Dr. Iravani presents a patient case to illustrate challenges faced in treatment progression, highlighting the patient’s journey through various therapies inclu...
|
- Details
- Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis, a Physician Assistant, and Sarah Wood, a Nurse Practitioner. Kristen describes the meticulous process of vetting patients for PLUVICTO® therapy, which includes reviewing patient information, scans, and coordinating with various departments for approval. Sarah outlines he...
|
- Details
- Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy (RLT). Dr. Parent emphasizes the critical importance of accurately identifying patients through PSMA PET imaging to ensure successful outcomes with Pluvicto therapy. He outlines the standardized practice of evaluating patients with PSMA PET to detect PSMA-...
|
